Granted Patent
B2
US 9,193,749 · App. 13/767,478 · Granted Nov 24, 2015
Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.
Claims (4)
1. A method of inhibiting histone deacetylase, comprising contacting the histone deacetylase with a pharmaceutical composition comprising:
i) (Z)-4-(dibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof; and
ii) a pharmaceutically acceptable carrier, excipient, or diluent.
2. A method of inhibiting histone deacetylase, comprising contacting the histone deacetylase with (Z)-4-(dibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof.
Assignments (4)
SECURITY INTEREST
Recorded Jul 5, 2016
From: FORUM PHARMACEUTICALS INC.
To: FMR LLC
Reel/Frame 039254/0828 →
CHANGE OF NAME
Recorded Oct 29, 2014
From: ENVIVO PHARMACEUTICALS, INC.
To: FORUM PHARMACEUTICALS, INC.
Reel/Frame 034086/0947 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 5, 2014
From: SHAPIRO, GIDEON; CHESWORTH, RICHARD
To: ENVIVO PHARMACEUTICALS
Reel/Frame 032356/0327 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 5, 2014
From: DEZIEL, ROBERT; LEIT, SILVANNA; BEAULIEU, PATRICK; CHANTIGNY, YVES ANDRE; MANCUSO, JOHN; TESSIER, PIERRE; SMIL, DAVID
To: METHYLGENE INC.
Reel/Frame 032356/0479 →